-$0.45 Earnings Per Share Expected for TG Therapeutics Inc (TGTX) This Quarter

Wall Street analysts predict that TG Therapeutics Inc (NASDAQ:TGTX) will post earnings per share (EPS) of ($0.45) for the current quarter, according to Zacks. Three analysts have issued estimates for TG Therapeutics’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.41). TG Therapeutics reported earnings of ($0.46) per share in the same quarter last year, which would indicate a positive year over year growth rate of 2.2%. The company is scheduled to announce its next earnings results on Thursday, March 14th.

On average, analysts expect that TG Therapeutics will report full-year earnings of ($2.03) per share for the current financial year, with EPS estimates ranging from ($2.10) to ($1.98). For the next fiscal year, analysts expect that the company will report earnings of ($1.60) per share, with EPS estimates ranging from ($2.06) to ($0.96). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.43) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.12. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 185.20% and a negative net margin of 99,001.33%.

A number of research firms have issued reports on TGTX. ValuEngine downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, September 17th. Raymond James downgraded TG Therapeutics from a “strong-buy” rating to an “outperform” rating and cut their price target for the company from $22.00 to $12.00 in a research note on Tuesday, September 25th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of TG Therapeutics in a research note on Friday, November 2nd. LADENBURG THALM/SH SH set a $27.00 price target on TG Therapeutics and gave the company a “buy” rating in a research note on Wednesday, September 26th. Finally, Zacks Investment Research upgraded TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a research note on Friday, November 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $18.35.

A number of hedge funds have recently added to or reduced their stakes in TGTX. BlackRock Inc. lifted its position in shares of TG Therapeutics by 8.3% during the 3rd quarter. BlackRock Inc. now owns 4,420,852 shares of the biopharmaceutical company’s stock worth $24,757,000 after buying an additional 339,802 shares in the last quarter. RA Capital Management LLC lifted its position in shares of TG Therapeutics by 73.1% during the 2nd quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock worth $56,266,000 after buying an additional 1,806,452 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of TG Therapeutics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,058,080 shares of the biopharmaceutical company’s stock worth $17,125,000 after buying an additional 268,483 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of TG Therapeutics by 2,148.1% during the 2nd quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock worth $11,686,000 after buying an additional 849,233 shares in the last quarter. Finally, Highland Capital Management LP lifted its position in shares of TG Therapeutics by 60.5% during the 3rd quarter. Highland Capital Management LP now owns 753,151 shares of the biopharmaceutical company’s stock worth $4,218,000 after buying an additional 283,910 shares in the last quarter. Institutional investors and hedge funds own 57.30% of the company’s stock.

Shares of TGTX traded up $0.04 during trading hours on Thursday, hitting $5.04. The stock had a trading volume of 1,552,400 shares, compared to its average volume of 1,348,560. The company has a market cap of $414.49 million, a PE ratio of -2.64 and a beta of 1.72. TG Therapeutics has a 1-year low of $4.20 and a 1-year high of $17.35.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Featured Article: Yield Curve

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply